A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease (ILLUSTRATE)

Pfizer

Status and phase

Completed

Phase 3

Conditions

Hyperlipidemia

Coronary Arteriosclerosis

Coronary Disease

Treatments

Drug: torcetrapib/atorvastatin

Drug: atorvastatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00134173

A5091005

Details and patient eligibility

About

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease

Full description

For additional information please call: 1-800-718-1021

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

angiographic evidence of coronary atherosclerosis

Exclusion criteria

Women who are pregnant or lactating, or planning to become pregnant.
Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid.
Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.